Calypte Only Company with Full Menu of Tests.

Mit der Reaktion magst du Recht haben,ist auch gut so,denn mit der Meldung, dass Calypte die Zulassung in China für seinen HIV Speichel Rapid test erhalten hat wird auch die Reaktion da sein, die du jetzt vermisst hast.

Fakt sind 25.000 tests, die geordert wurden, dies sollte man als Meilenstein ansehen, die Finanziellen Eckdaten wurden mehremale angesprochen, die werden sich erstmal nicht ändern, Fakt ist, wenn Calypte es gelingt 300.000 tests im Mo. abzusetzen, somit hätte man den Break Even..  

Davon sind jetzt die ersten 5 um...

LAKE OSWEGO, Ore., July 13 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Nachrichten) (the "Company"), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market for the detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has received an initial order for 35,500 units of its Aware(TM) HIV-1/2 oral fluid rapid test. This initial order has been placed through Gennaria Comercio International Lda on behalf of MineSeeker Foundation and will be sold through Calypte's exclusive distributors in Africa once final destinations are known. Calypte currently has approval to sell its rapid oral fluid test in South Africa and Kenya. Based on Calypte's communications with MineSeeker, this is the first firm order of a series of orders totaling 1.0 million tests that MineSeeker intends placing with Calypte over the next 12 months.



Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

 

 

GALE?

naja, da kommt was...

wahrscheinlich die initialorder über 15.000 teile ode die zulassung zum verkauf des testes in west-samoa.

rund 1.000.000 teile im vergleich zu 221.000.000 outstanding shares ist wohl nicht die welt, oder? auch wenn 775.000$ dahinter stehen.

ein kurzer zucker, womöglich macht caly euch ja mit 0,10$ ein überraschendes weihnachtsgeschenk. dann sind hier wieder alle seelig von 33% anstieg, obwohl man selber noch 80% im minus ist.

naja, so belügen sich halt die investoren selber...  

 

 

Calypte Announces Results of 2006 Annual Stockholders' Meeting
Monday December 18, 8:30 am ET

CEO Comments on Progress Toward Chinese SFDA Approval

LAKE OSWEGO, Ore., Dec. 18 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market today announced the results of its 2006 Annual Stockholders' Meeting held on December 15, 2006 at its headquarters location in Lake Oswego, Oregon.

The Company reported that its stockholders approved the following proposals:

    1. To re-elect the five current directors of the Company; Mr. Roger I.       Gale, Chairman and Chief Executive Officer; Mr. John J. DiPietro; Mr.       Paul E. Freiman; Dr. Julius R. Krevans, M.D; and Mr. Maxim A. Soulimov,       who will hold office until the next Annual Meeting of Stockholders or       until their successors are elected; and    2. To ratify the appointment by the Audit Committee and the Board of       Directors of Odenberg Ullakko Muranishi & Co. LLP ("OUM") as the       independent registered public accounting firm to audit the Company's       financial statements for the fiscal year ending December 31, 2006.

Mr. Roger Gale provided an update to the Stockholders in attendance, commenting on recent sales progress in the regions where the Company has approval of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test, specifically Russia, the Middle East and Africa. When asked about a sales outlook, Mr. Gale acknowledged the difficulty of estimating the results from these early- stage efforts, but indicated that the company is internally forecasting sales in the range of $4.5 million to $4.7 million for 2007. Although the Company does not expect this sales level to result in cash flow breakeven, it is optimistic that sales could exceed this level as several of the initiatives, including high-profile charities, certain private sector groups, and various government agencies could each result in significant sales demand.

Mr. Gale was also optimistic concerning the progress in China, stating "Dr. Ron Mink, Calypte's Chief Science Officer, was invited to attend the Chinese State Food and Drug Administration's ("SFDA") Expert Panel Meeting held on December 4, 2006 in Beijing, China, where the Company made a presentation and answered technical questions before a panel of 10 experts regarding its Aware(TM) HIV-1/2 OMT test. The SFDA has an approval process similar to that of the U.S. FDA and in that respect, this presentation is one of the later parts of the process. Although the panel needs to review the inputs from the meeting as well as other information in reaching its decision on our application, we think the meeting went well and that we satisfactorily addressed all of the panel's questions. We will continue to keep you informed as we prepare for our sales launch in China."

Mr. Gale continued, "Our factory in China has been readied for the production of our Aware(TM) products; equipment is in place and personnel have been trained. When we have completed our GMP approval, we expect to be able to supply both the Chinese and export markets, as sales demand dictates. We have a planned capacity of approximately 10 million tests per month and, through our joint venture, own land for expansion as needed. We are optimistic about our opportunity to serve the Chinese market and other key regions where the HIV/AIDS pandemic is expected to grow over the next several years. We believe our efforts to help identify HIV infections in a simple, quick and non-invasive way will be a part of the solution in helping to bring the disease under control."

 

 

CALYPTE BIOMEDICAL CORP filed this Form 8-K on 12/18/06

<< Previous Page | Next Page >>

UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2006  Calypte Biomedical Corporation(Exact name of Company as specified in its charter) Delaware   000-20985   06-1226727 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification)  5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (971) 204-0282 N/A (Former name or former address, if changed since last report) o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))   Item 7.01 - Regulation FD Disclosure.  On December 15, 2006, Calypte Biomedical Corporation (the “Company”) held its 2006 Annual Meeting of Stockholders at which the Company’s stockholders re-elected all current members of its Board of Directors, including Roger I. Gale, John J. DiPietro, Paul E. Freiman, Julius R. Krevans, M.D., and Maxim A. Soulimov, to serve until the next Annual Meeting of Stockholders or until their successors are elected and ratified the appointment of Odenberg Ullakko Muranishi & Co. LLP as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the year ending December 31, 2006.  Mr. Roger Gale, the Company’s Chairman and Chief Executive Officer, provided an update to the Stockholders in attendance, commenting on recent sales progress in the regions where the Company has approval of its Aware™ HIV-1/2 OMT (oral fluid) rapid test, specifically Russia, the Middle East and Africa and also provided an update regarding the status of the Company’s approval process for its OMT rapid test in China. In response to a question regarding the Company’s sales outlook, Mr. Gale responded that the Company is forecasting 2007 revenues in the range of $4.5 million to $.4.7 million, which would not result in the Company reaching a cash flow breakeven point. A copy of the Company’s press release announcing the results of its Annual Stockholders Meeting and Mr. Gale’s other comments is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.  Item 9.01 - Financial Statements and Exhibits.  (d) Exhibits   Exhibit Number    Description 99.1    Calypte Biomedical Corporation Press Release dated December 18, 2006.         SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  Date:  December 18, 2006       Calypte Biomedical Corporation               By:   /s/ Theodore R. Gwin     Theodore R. GwinChief Financial Officer   Exhibit 99.1   NEWS RELEASE   5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97034   www.calypte.com           Company Contact: Investor Relations Contact:   Theodore R Gwin, Chief Financial Officer Tim Clemensen,   (971) 204-0282 Rubenstein Investor Relations   email:tgwin@calypte.com Phone: (212) 843-9337     email:tclemensen@rubensteinir.com   Calypte Announces Results of 2006 Annual Stockholders’ MeetingCEO Comments on Progress Toward Chinese SFDA Approval Lake Oswego, OR - December 18, 2006 - Calypte Biomedical Corporation (OTCBB: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market today announced the results of its 2006 Annual Stockholders’ Meeting held on December 15, 2006 at its headquarters location in Lake Oswego, Oregon. The Company reported that its stockholders approved the following proposals: 1. To re-elect the five current directors of the Company; Mr. Roger I. Gale, Chairman and Chief Executive Officer; Mr. John J. DiPietro; Mr. Paul E. Freiman; Dr. Julius R. Krevans, M.D; and Mr. Maxim A. Soulimov, who will hold office until the next Annual Meeting of Stockholders or until their successors are elected; and 2. To ratify the appointment by the Audit Committee and the Board of Directors of Odenberg Ullakko Muranishi & Co. LLP (“OUM”) as the independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2006.  Mr. Roger Gale provided an update to the Stockholders in attendance, commenting on recent sales progress in the regions where the Company has approval of its Aware™ HIV-1/2 OMT (oral fluid) rapid test, specifically Russia, the Middle East and Africa. When asked about a sales outlook, Mr. Gale acknowledged the difficulty of estimating the results from these early-stage efforts, but indicated that the company is internally forecasting sales in the range of $4.5 million to $4.7 million for 2007. Although the Company does not expect this sales level to result in cash flow breakeven, it is optimistic that sales could exceed this level as several of the initiatives, including high-profile charities, certain private sector groups, and various government agencies could each result in significant sales demand.   Mr. Gale was also optimistic concerning the progress in China, stating “Dr. Ron Mink, Calypte’s Chief Science Officer, was invited to attend the Chinese State Food and Drug Administration’s (“SFDA”) Expert Panel Meeting held on December 4, 2006 in Beijing, China, where the Company, made a presentation and answered technical questions before a panel of 10 experts regarding its Aware™ HIV-1/2 OMT test. The SFDA has an approval process similar to that of the U.S. FDA and in that respect, this presentation is one of the later parts of the process. Although the panel needs to review the inputs from the meeting as well as other information in reaching its decision on our application, we think the meeting went well and that we satisfactorily addressed all of the panel’s questions. We will continue to keep you informed as we prepare for our sales launch in China.” Mr. Gale continued, “Our factory in China has been readied for the production of our Aware™ products; equipment is in place and personnel have been trained. When we have completed our GMP approval, we expect to be able to supply both the Chinese and export markets, as sales demand dictates. We have a planned capacity of approximately 10 million tests per month and, through our joint venture, own land for expansion as needed. We are optimistic about our opportunity to serve the Chinese market and other key regions where the HIV/AIDS pandemic is expected to grow over the next several years. We believe our efforts to help identify HIV infections in a simple, quick and non-invasive way will be a part of the solution in helping to bring the disease under control.” About Calypte Biomedical: Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the AwareTM HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.  Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company’s ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC.

 

 

 Mr. Roger Gale provided an update to the Stockholders in attendance, commenting on recent sales progress in the regions where the Company has approval of its Aware™ HIV-1/2 OMT (oral fluid) rapid test, specifically Russia, the Middle East and Africa. When asked about a sales outlook, Mr. Gale acknowledged the difficulty of estimating the results from these early-stage efforts, but indicated that the company is internally forecasting sales in the range of $4.5 million to $4.7 million for 2007. Although the Company does not expect this sales level to result in cash flow breakeven, it is optimistic that sales could exceed this level as several of the initiatives, including high-profile charities, certain private sector groups, and various government agencies could each result in significant sales demand.  

---

Mr. Gale was also optimistic concerning the progress in China, stating “Dr. Ron Mink, Calypte’s Chief Science Officer, was invited to attend the Chinese State Food and Drug Administration’s (“SFDA”) Expert Panel Meeting held on December 4, 2006 in Beijing, China, where the Company, made a presentation and answered technical questions before a panel of 10 experts regarding its Aware™ HIV-1/2 OMT test. The SFDA has an approval process similar to that of the U.S. FDA and in that respect, this presentation is one of the later parts of the process. Although the panel needs to review the inputs from the meeting as well as other information in reaching its decision on our application, we think the meeting went well and that we satisfactorily addressed all of the panel’s questions. We will continue to keep you informed as we prepare for our sales launch in China.” Mr. Gale continued, “Our factory in China has been readied for the production of our Aware™ products; equipment is in place and personnel have been trained. When we have completed our GMP approval, we expect to be able to supply both the Chinese and export markets, as sales demand dictates. We have a planned capacity of approximately 10 million tests per month and, through our joint venture, own land for expansion as needed. We are optimistic about our opportunity to serve the Chinese market and other key regions where the HIV/AIDS pandemic is expected to grow over the next several years. We believe our efforts to help identify HIV infections in a simple, quick and non-invasive way will be a part of the solution in helping to bring the disease under control.” 

 

leisten in China..  

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

Durch eine engere Zusammenarbeit und intensiven Austausch mit internationalen Organisationen will die chinesische Regierung den Kampf gegen AIDS forcieren. Dies erklärte die stellvertretende chinesische Ministerpräsidentin Wu Yi am Mittwoch in Beijing bei einem Treffen mit der UN-Sonderbeauftragten für HIV und AIDS im asiatisch-pazifischen Raum, Nafis Sadik.
Die chinesische Regierung lege großen Wert auf eine gewissenhafte Vorbeugung vor AIDS und auf eine gezielte Kontrolle der Krankheit, hierzu wurde ein Regierungsprogramm ins Leben gerufen. Auch die Koordination der verschiedenen Verwaltungsabteilungen wurde optimiert. Die chinesische Gesellschaft sei in diesen Prozess eingebunden. Die Zahl der HIV-Infizierten in China soll bis 2010 1,5 Millionen nicht überschreiten. China begrüße, erklärte Wu abschließend, dass die entsprechenden UN-Organisationen China bei der AIDS-Prävention mehr Unterstützung und Hilfe zugesagt haben.
(China.org.cn, 7. Dezember 2006)
 

...Die chinesische Regierung lege großen Wert auf eine gewissenhafte Vorbeugung vor AIDS und auf eine gezielte Kontrolle der Krankheit....  

diese Kontrolle wird wenn überhaupt durch Tests von Trip und Orasure durchgeführt und nicht Calypte die ein Werk in China haben, diese 10.000.000 Tests im Monat produzieren können.
Lucky  

in 2007 wird es uns allen besser gehen..  

sind auch die 30 Tage um, bald werden News fällig...  

Es müssen nicht irgendwelche News kommen sondern die auf die wir Jahre warte .... denn an News haben wir ja genug bekommen !!!

WARMDUSCHER MELDUNGEN mit Volksverdümmung !  

vor allem hier von volksverdummung zu sprechen. wie kannst du das gegenüber lucky und broker so sagen?
gerade, wo bei denen die volksverdummung schon funktioniert hat....


muhahahahahahahahaha  

Joelu eines Tages wird das passieren  

 

Dieses Jahr wird sich Entscheiden Joelu ... genauer gesagt die ersten 6 Monate wenn sich bis dahin nicht einmal die Hälfte ihrer Umsätze generieren werde ich wirklich das Caly Kapitel ablegen .... du hast ja zum Teil recht mit deiner Meinung nun sind es fast
9 Jahre .... neun Jahre wo die uns für Dumm verkaufen wollen und tuhen.

Und in diesen 6 Monate werde ich jeden Cent in Caly stecken ........

Das heisst ich lade noch ein letztes Mal die Kanone ....
( gutes Gefühl habe ich nicht eher bisshen zu Naiv )  

Damit sich Joelu wieder amüsiert .... die Caly Gewinne von 2003 sind aufgebraucht bei mir und liegen seid ein paar Monaten sogar im Minus ..... ARGHHHHHHH  

calygewinne aufgebraucht sind, calyritter.

trotz deiner nie eingehaltenen zusage zur begleichung unserer champagner-wette rechne ich dir hoch an, dass du das hier so freimütig zugibst.

natürlich liegt das auf der hand, dass hier alle im minus sind. so tief wie jetzt war der kurs ja auch noch nie. zugeben, vor allem öffentlich dazu stehen, tun nur die wenigsten. die meisten belügen sich lieber weiter selber, so wir lucky und brokersince.

du bist auf dem wege zur einsicht, calyritter. jedoch würd eich deinem schönen verbrannten geld nicht noch weiter gutes hinterher werfen.

auch ehrt dich, das du wenigstens "zum teil einsiehst", dass ich recht hatte vom trend her mit meinen caly-prognosen. wenn du das ding mal richtig verdaut hast, wirst du sogar sehen, dass ich vollkommen recht hatte. nicht imemr auf den zeitpunkt genau. aber den kurs punktuell vorauszusagen ist ebn selten möglich. nur eines solltest du dir vor augen führen:

die von mir lange vorhergesagten 10cent und weniger habt ihr schon lange erreicht. ebenso den verlust des amex-listings habe ich allen spöttern zum trotze richtig prognostiziert...

hättest du mal eher auf mich gehört und nicht auf die realitätsverweigerer, die in ihren durchhalteparolen nur noch ihren eigennutz suchen, um ihre verluste zu minimieren, ginge es dir jetzt besser!  

3418. du brauchst mal richtiges auf die Fresse   LuckyStrike   04.01.07 11:31  

Joelu eines Tages wird das passieren
--------------------------------------------------

caly hat zumindestens dir schon richtig die fresse poliert, um mal bei deiner wortwahl zu bleiben. und caly wird es weiterhin tun. das wird soweit gehen, dass du irgendwann ganz ohne zähne bist. du wirst nicht mal die kohle haben, dir neue zu kaufen. aber das bist du selber schuld. wer naiv und sinnentleert dabei zusieht und auch noch stillhält, der verdient es wohl nicht besser...
 

3419. Der Joelü hat wirklich ein gewalltiges problem o. T.   OttomanRosend.   04.01.07 12:20  
--------------------------------------------------

dein problem mit caly ist wohl ein wesentlich größeres als meines. du weißt es nur noch nicht, weil du getreu einem nicht-denkenden-caly-aktionär immer noch deine rosarote brille und die scheuklappen auf hast.

wahrscheinlich wirst du es erst merken, welchen wahnsinn dun hier begehst, wenn dich deine letzte stunde ereilt hat...frei nach deinem persönlichen leitsatz in deinem userprofil!

welche ironie des schicksals...
 

Meine Meinung zur deiner Person oder deiner Persönlichkeit kennst du ja und die ist ja nur der Spiegelbild deines eigenen ich's ...

Seit über 6 Jahren versuchst du vergeblich uns investierten zu beleidigen aber wie gesagt ohne Erfolg... Deine Eigenen Anlagen die ja zur seiner Zeit Suuupeer laufen sollten sind mitlerweile ja auch den Bach runter-gelaufen anstatt die Frust dort rauszulassen versuchst du unser investment hier schlecht darzustellen... Der Unterschied zwischen uns und dir ist , das wir Aussichten haben du mit deinen Anlagen hast leider keine Hoffnung und das passt dir wohl nicht anders kann ich dich nicht entschlüsseln...muhahahahahahahahahhaa